© 2004 by Oxford University Press
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
© 2004 Oxford University Press
ARTICLE |
Treatment of Axillary Lymph Node–Negative, Estrogen Receptor–Negative Breast Cancer: Updated Findings From National Surgical Adjuvant Breast and Bowel Project Clinical Trials
Affiliations of authors: National Surgical Adjuvant Breast and Bowel Project, Operations Center (BF, NW), and Biostatistical Center, Department of Biostatistics and University of Pittsburgh, Graduate School of Public Health (JHJ, SA)
Correspondence to: Bernard Fisher, 4 Allegheny Center, Suite 602, Pittsburgh, PA, 15212-5234 (e-mail: bernard.fisher{at}nsabp.org)
Background: Results from three National Surgical Adjuvant Breast and Bowel Project sequentially conducted randomized trials of postoperative chemotherapy in women with estrogen receptor–negative tumors and negative axillary lymph nodes have demonstrated that a combination of methotrexate and 5-fluorouracil (MF) is more effective than surgery alone, that cyclophosphamide with MF (CMF) is more effective than MF, and that CMF and doxorubicin (Adriamycin) with cyclophosphamide (AC) are equally beneficial. This report presents updated findings from those trials, relates the results to age and menopausal status, and estimates the extent of progress made in treating such patients. Methods: Patients were randomly assigned as follows: in B-13, 760 patients were assigned to surgery only or to MF; in B-19, 1095 patients were assigned to MF or CMF; in B-23, 2008 patients were assigned to CMF or AC. Recurrence-free survival (RFS) and overall survival (OS) were estimated according to age and menopausal status. Smoothed recurrence rates were used to evaluate patterns of recurrence as a continuous function of age. The Cox proportional hazards model was used to test for interactions between treatment and covariates and to estimate hazard ratios (HRs) for pairwise group comparisons. Results: In B-13, through 16 years of follow-up, an overall benefit was seen with MF relative to surgery alone (RFS: HR = 0.59, 95% confidence interval [CI] = 0.44 to 0.78, P<0.001; OS: HR = 0.75, 95% CI = 0.58 to 0.98, P = 0.03). In B-19, through 13 years of follow-up, an overall benefit was seen for CMF relative to MF (RFS: HR = 0.59, 95% CI = 0.45 to 0.77, P<0.001; OS: HR = 0.71; 95% CI = 0.55 to 0.92; P = 0.01). In both trials, all age and menopausal groups demonstrated an RFS benefit, and most demonstrated an OS benefit. In B-23, through 8 years of follow-up, there were no statistically significant differences between the CMF and AC groups (RFS: HR = 1.00, 95% CI = 0.79 to 1.27, P = 0.97; OS, HR = 0.92, 95% CI = 0.73 to 1.17; P = 0.51). When women in the CMF or AC groups (B-19, B-23) were compared with those who were in the surgery-alone group (B-13), through 8 years of follow-up there was a 58% reduction in recurrence and a 40% reduction in mortality as a result of the chemotherapy. Conclusions: Outcomes in CMF- or AC-treated women with estrogen receptor–negative tumors and negative axillary lymph nodes were similar in all age groups. The decreased benefit from chemotherapy observed with increasing age was a result of a better outcome associated with advancing age in women who underwent surgery alone rather than a poorer outcome resulting from the use of chemotherapy.
CiteULike 
Connotea 
Del.icio.us What's this?
Editorial about this Article
- Adjuvant Chemotherapy for Lymph Node–Negative, Estrogen Receptor–Negative Breast Cancer: A Tale of Three Trials
- Kathy S. Albain
J Natl Cancer Inst 2004 96: 1801-1804.[Extract] [Full Text] [PDF]
This article has been cited by other articles:
|
|
 |
|
  S. J. Anderson, I. Wapnir, J. J. Dignam, B. Fisher, E. P. Mamounas, J.-H. Jeong, C. E. Geyer Jr, D. L. Wickerham, J. P. Costantino, and N. Wolmark Prognosis After Ipsilateral Breast Tumor Recurrence and Locoregional Recurrences in Patients Treated by Breast-Conserving Therapy in Five National Surgical Adjuvant Breast and Bowel Project Protocols of Node-Negative Breast Cancer J. Clin. Oncol., May 20, 2009; 27(15): 2466 - 2473. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. T. Ross, C.-y. Kim, G. Tang, O. L. Bohn, R. A. Beck, B. Z. Ring, R. S. Seitz, S. Paik, J. P. Costantino, and N. Wolmark Chemosensitivity and Stratification by a Five Monoclonal Antibody Immunohistochemistry Test in the NSABP B14 and B20 Trials Clin. Cancer Res., October 15, 2008; 14(20): 6602 - 6609. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Fisher, C. K. Redmond, and E. R. Fisher Evolution of Knowledge Related to Breast Cancer Heterogeneity: A 25-Year Retrospective J. Clin. Oncol., May 1, 2008; 26(13): 2068 - 2071. [Full Text] [PDF]
|
|
|
|
|
|
G. Viale, M. M. Regan, E. Maiorano, M. G. Mastropasqua, R. Golouh, T. Perin, R. W. Brown, A. Kovacs, K. Pillay, C. Ohlschlegel, et al. Chemoendocrine Compared With Endocrine Adjuvant Therapies for Node-Negative Breast Cancer: Predictive Value of Centrally Reviewed Expression of Estrogen and Progesterone Receptors--International Breast Cancer Study Group J. Clin. Oncol., March 20, 2008; 26(9): 1404 - 1410. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J.-H. Jeong and J. P. Fine Parametric regression on cumulative incidence function Biostat., April 1, 2007; 8(2): 184 - 196. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Richardson Re: Ethnicity and Breast Cancer: Factors Influencing Differences in Incidence and Outcome J Natl Cancer Inst, November 2, 2005; 97(21): 1619 - 1619. [Full Text] [PDF]
|
|
|
|
 |
|
 A. Goldhirsch, J. H. Glick, R. D. Gelber, A. S. Coates, B. Thurlimann, H.-J. Senn, and and Panel Members Meeting Highlights: International Expert Consensus on the Primary Therapy of Early Breast Cancer 2005 Ann. Onc., October 1, 2005; 16(10): 1569 - 1583. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. P. Mamounas Can We Approach Zero Relapse in Breast Cancer? Oncologist, October 1, 2005; 10(suppl_2): 9 - 17. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. S. Albain Adjuvant Chemotherapy for Lymph Node-Negative, Estrogen Receptor-Negative Breast Cancer: A Tale of Three Trials J Natl Cancer Inst, December 15, 2004; 96(24): 1801 - 1804. [Full Text] [PDF]
|
|